This article was originally published in The Tan Sheet
IVAX Pharmaceuticals is issuing a voluntary recall of Goldline Extra Strength Genapap and Extra Strength Genebs (both 500 mg acetaminophen) in caplet and tablet form, FDA announces May 2. The Miami, Fla.-based firm is recalling 30 lots due to a labeling error, according to the agency. The product labels should indicate that usage is not to exceed eight tablets/caplets in a 24-hour period; however, the erroneous label indicates not to exceed 12 tablets/caplets in a 24-hour period. If more than eight tablets/caplets are ingested in a 24-hour period, patients may face an increased risk of acetaminophen toxicity to the liver, FDA notes. Consumers are urged to "cease usage and return the product to the location of purchase." Retailers and wholesalers are encouraged to return all unsold lots to IVAX...
You may also be interested in...
The entry of India’s state-owned Indian Immunologicals and partner Griffith University in the COVID-19 vaccine race could potentially disrupt pricing dynamics. The alliance is developing a live-attenuated, single dose vaccine, which it hopes will be ready for launch in 18-24 months.
Shortly after wrapping up a Phase III trial for its proposed generic Advair Diskus product in the US, Cipla has won FDA approval for the first generic Proventil HFA product, as it continues to build up steam in the US respiratory market.
The UK's MHRA is looking for manufacturers to submit COVID-19 self-tests that meet minimum and desired criteria for evaluation, after finding its recently purchased 3.5m self-tests failed to meet these standards. Criteria include no requirement for testing knowledge or training or assistance from a healthcare professional in administering or interpreting the results of the test, as well as a 95% accuracy level.